Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of ST-920 gene therapy in Fabry disease
2024-512700-18-00Phase 2Authorised
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Apr 2025
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of isaralgagene civaparvovec in Fabry disease (FD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety of ST-920. Planned start Apr 2025; status: authorised.
02
Drugs
isaralgagene civaparvovec
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2024-512700-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512700-18-00.